Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
基本信息
- 批准号:9301688
- 负责人:
- 金额:$ 99.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-05 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute myocardial infarctionAddressAdjuvantAdverse effectsAlteplaseAmericanAnticoagulantsAnticoagulationAwardBiological AssayBiomedical EngineeringBleeding time procedureBloodBlood VesselsBlood coagulationCaringCause of DeathClinicalClinical TrialsCoagulation ProcessCombined Modality TherapyCoronary StenosisDevelopmentDisease ProgressionDoseDrug ExposureDrug InteractionsEarly treatmentEmergency SituationEngineeringEnzyme ActivatorsEnzymesFibrinolytic AgentsFundingGMP lotsGoalsGrantHeartHemorrhageHemostatic AgentsHemostatic functionHospitalsHourHoward Temin AwardHumanImmune responseImpairmentInterruptionIowaIschemic StrokeLeadLicensingLifeMeasurableMeasuresModalityModelingMonkeysMusMyocardial InfarctionMyocardial IschemiaPapioPathologicPatientsPercutaneous Transluminal Coronary AngioplastyPetechiaePharmaceutical PreparationsPhasePhase I Clinical TrialsPlasmaPositioning AttributePrimatesProductionProtein CProteinsPurpuraRattusRecombinantsReperfusion TherapyRiskRuptureSafetySavingsSecureSiteSmall Business Innovation Research GrantSurfaceTestingTherapeuticThrombinThrombolytic TherapyThrombomodulinThrombusTimeToxic effectToxicologyUnited StatesUnited States National Institutes of HealthVascular GraftVascular Graft Occlusionactivated Protein Cacute coronary syndromeanalogattack victimbioprocesscellular targetingcommercializationcoronary artery occlusiondesigndrug candidateimprovedimproved outcomein vivoinnovationnonhuman primatepercutaneous coronary interventionpre-clinicalpre-clinical researchproduct developmentprogramssafety studytherapeutic proteinthrombolysistreatment strategy
项目摘要
PROJECT SUMMARY
Heart attack, or acute myocardial infarction (AMI), is a leading cause of death in the United States, with over
700,000 victims every year. The most prevalent cause of AMI is progressive thrombotic coronary artery
occlusion, also known as ST-segment elevation myocardial infarction (STEMI). Early therapy to promote heart
reperfusion can dramatically improve outcomes. While percutaneous coronary intervention (PCI) is preferred
for early arterial recanalization, up to 70% of patients present to hospitals without this capability, and many
STEMI victims must rely on thrombolytic therapy alone. However, current thrombolytics such as tissue
plasminogen activator (tPA) are not fully effective, and many patients are excluded from thrombolytic therapy
altogether due to bleeding concerns. Consequently, a major treatment gap exists for hemostatically safe
antithrombotic and thrombolytic drugs that can be used alone or that can improve the efficacy of current
treatments without increased bleeding. To directly address this need, our company has been developing a first-
in-class antithrombotic agent for the safe treatment of heart attack. The product candidate is a bioengineered
recombinant selective protein C activator enzyme that has potent antithrombotic effects without increasing
hemorrhagic risks. Our proprietary molecule, ProCase (E-WE thrombin) has been designed to act in part by
increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme,
endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This
unique mechanism of action allows E-WE thrombin to target pathological blood clots without disabling vital
hemostasis. In primates, doses as low as 1 µg/kg are antithrombotic without systemic anticoagulation or any
antihemostatic effects. All of the critical milestones for our Fast-Track SBIR Phase I/II grant have been reached
to justify progression to Phase IIB by demonstrating: 1) E-WE thrombin is effective in a mouse AMI model; 2)
E-WE thrombin safely interrupts vascular graft thrombo-occlusion in primates; 3) Our sensitive blood assay can
measure drug exposure levels in plasma; and 4) Limited repeat administration of E-WE thrombin does not
evoke an immune response in primates. Our Phase IIB aims that will support critical product development
milestones are to: 1) Determine the antithrombotic efficacy and hemostatic safety of combining E-WE thrombin
plus tPA in primates; 2) Complete a bridging preclinical GLP toxicology study of E-WE thrombin combined with
tPA; and 3) Transfer E-WE thrombin manufacturing to a facility capable of commercial scale production. We
are currently at a critical juncture for advancing E-WE thrombin towards human trials to treat STEMI, and
ultimately all acute coronary syndrome (ACS) patients. This SBIR Phase IIB Bridge Award, matched by a
combination of already secured and pending funds, will lead directly to the initiation of clinical trials
investigating this unique and potentially life-saving antithrombotic drug candidate.
项目摘要
心脏病发作或急性心肌梗死(AMI)是美国的主要死亡原因,
每年有70万受害者。急性心肌梗死最常见的原因是进行性血栓性冠状动脉
闭塞,也称为ST段抬高心肌梗死(STEMI)。早期治疗促进心脏
再灌注可以显著改善结果。虽然经皮冠状动脉介入治疗(PCI)是首选
对于早期动脉再通,高达70%的患者到医院就诊时没有这种能力,
STEMI患者必须单独依靠溶栓治疗。然而,目前的溶栓剂,如组织溶栓剂,
纤溶酶原激活剂(tPA)并不完全有效,许多患者被排除在溶栓治疗之外
完全是因为担心出血因此,止血安全性存在重大治疗差距
可以单独使用或可以改善当前治疗的功效的抗血栓形成和血栓溶解药物。
治疗不会增加出血。为了满足这一需求,我们公司开发了第一个-
安全治疗心脏病发作的同类抗血栓药物。候选产品是生物工程
重组选择性蛋白C激活酶,其具有有效的抗血栓形成作用而不增加
出血风险。我们的专有分子ProCase(E-WE凝血酶)被设计为部分通过以下方式发挥作用:
增加抗凝剂、纤溶酶原和细胞保护酶的表面浓度,
内源性活化蛋白C(APC),通过靶向细胞递送在形成血凝块的部位。这
独特的作用机制使E-WE凝血酶能够靶向病理性血凝块,而不会使重要的
止血。在灵长类动物中,低至1 µg/kg的剂量具有抗血栓作用,而无需全身抗凝或任何
抗止血作用。我们的快速通道SBIR第I/II阶段赠款的所有关键里程碑都已达到
通过证明:1)E-WE凝血酶在小鼠AMI模型中有效; 2)
E-WE凝血酶安全地阻断灵长类动物血管移植物血栓闭塞; 3)我们的灵敏血液检测可以
测量血浆中的药物暴露水平;以及4)E-WE凝血酶的有限重复施用不
引起灵长类动物的免疫反应。我们的IIB阶段旨在支持关键产品开发
里程碑是:1)确定联合E-WE凝血酶的抗血栓疗效和止血安全性
2)完成E-WE凝血酶与tPA联合的桥接临床前GLP毒理学研究;
tPA;和3)将E-WE凝血酶制造转移到能够商业规模生产的设施。我们
目前正处于将E-WE凝血酶推向治疗STEMI的人体试验的关键时刻,
最终所有急性冠状动脉综合征(ACS)患者。这SBIR第IIB阶段桥梁奖,由一个匹配
已经获得的和待定的资金将直接导致临床试验的启动
研究这种独特的、可能挽救生命的抗血栓候选药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erik Ian Tucker其他文献
Erik Ian Tucker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erik Ian Tucker', 18)}}的其他基金
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10213549 - 财政年份:2019
- 资助金额:
$ 99.81万 - 项目类别:
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10378696 - 财政年份:2019
- 资助金额:
$ 99.81万 - 项目类别:
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10616494 - 财政年份:2019
- 资助金额:
$ 99.81万 - 项目类别:
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
HLS-表面引发血栓形成的因子 XII 抑制剂
- 批准号:
9324070 - 财政年份:2016
- 资助金额:
$ 99.81万 - 项目类别:
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
HLS-表面引发血栓形成的因子 XII 抑制剂
- 批准号:
9137247 - 财政年份:2016
- 资助金额:
$ 99.81万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8641021 - 财政年份:2013
- 资助金额:
$ 99.81万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8456004 - 财政年份:2013
- 资助金额:
$ 99.81万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8826804 - 财政年份:2013
- 资助金额:
$ 99.81万 - 项目类别:
相似海外基金
Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
- 批准号:
MR/Y009770/1 - 财政年份:2023
- 资助金额:
$ 99.81万 - 项目类别:
Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
- 批准号:
23K15160 - 财政年份:2023
- 资助金额:
$ 99.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
- 批准号:
10709134 - 财政年份:2023
- 资助金额:
$ 99.81万 - 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
- 批准号:
10603548 - 财政年份:2023
- 资助金额:
$ 99.81万 - 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10576349 - 财政年份:2022
- 资助金额:
$ 99.81万 - 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
- 批准号:
22K09185 - 财政年份:2022
- 资助金额:
$ 99.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
- 批准号:
22K08135 - 财政年份:2022
- 资助金额:
$ 99.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
- 批准号:
468573 - 财政年份:2022
- 资助金额:
$ 99.81万 - 项目类别:
Operating Grants
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10339915 - 财政年份:2022
- 资助金额:
$ 99.81万 - 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
- 批准号:
nhmrc : 2005797 - 财政年份:2021
- 资助金额:
$ 99.81万 - 项目类别:
Partnership Projects